[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100553018":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":34,"responsibleParty":50,"collaborators":11,"id":52,"slug":11,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":11,"eligibilityCriteria":56,"healthyVolunteers":53,"sex":57,"minAge":11,"maxAge":11,"enrollmentInfo":58,"targetDuration":11,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":11,"overallStatus":68,"whyStopped":11,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Anhui Provincial Hospital","OTHER_GOV",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"basiliximab group","EXPERIMENTAL",null,[13],"Drug: Basiliximab",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DRUG","Basiliximab","Addition of CD25 monoclonal antibody（Basiliximab） at +3 days post unrelated umbilical cord blood transplantation (UCBT)",[9],[21],{"name":22,"affiliation":23,"role":24},"Xiaoyu Zhu, Ph.D","The First Affiliated Hospital of USTC (Anhui Provincial Hospital)","PRINCIPAL_INVESTIGATOR",[26,30],{"name":22,"role":27,"phone":28,"phoneExt":11,"email":29},"CONTACT","15255456091","xiaoyuz@ustc.edu.cn",{"name":31,"role":27,"phone":32,"phoneExt":11,"email":33},"Kaidi Song, M.D","18715062778","kaidisong@163.com",[35],{"facility":36,"status":11,"city":37,"state":11,"zip":11,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital)","Hefei","China","CN",{"type":41,"coordinates":42},"Point",[43,44],117.28083,31.86389,{"lat":44,"lon":43},[47,49],{"name":22,"role":27,"phone":28,"phoneExt":11,"email":48},"xiaoyuz@ustc.cn",{"name":31,"role":27,"phone":32,"phoneExt":11,"email":33},{"type":51,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100553018",false,"NCT06480630","Effectiveness and Safety of a Single-Center Clinical Study on a CD25 Monoclonal Antibody-Containing GVHD Prophylaxis Scheme to Reduce the Incidence of Severe Acute GVHD After Umbilical Cord Blood Transplantation for Malignant Hematologic Diseases","Inclusion Criteria:\n\n* Malignant hematologic disorders;\n* Patients undergoing UCBT;\n* Female patients of childbearing potential must have a negative pregnancy test and agree to use effective contraception during treatment and for the following year.\n\nExclusion Criteria:\n\n* Non-malignant hematologic disorders;\n* History of allogeneic hematopoietic stem cell transplantation or solid organ transplantation;\n* Uncontrolled bacterial, viral, or fungal infections. \"Uncontrolled\" is defined as lack of clinical improvement or progression despite adequate antimicrobial therapy;\n* HIV infection or active hepatitis B or C virus infection;\n* Pregnant or lactating women;\n* Substance abusers; subjects with uncontrolled psychiatric disorders; individuals with cognitive dysfunction;\n* Participation in similar clinical studies within the past 3 months;\n* Subjects deemed unsuitable by the investigator (e.g., those expected to be unable to adhere to treatment due to financial constraints).","ALL",{"count":59,"type":60},39,"ESTIMATED","INTERVENTIONAL",[63],"PHASE2","Evaluating the safety and effectiveness of a CD25 monoclonal antibody-based prophylactic acute graft-versus-host-disease (aGVHD) regimen following unrelated umbilical cord blood transplantation (UCBT) for malignant hematologic disorders in reducing severe aGVHD.",[66,67],"Acute Graft Versus Host Disease","Malignant Hematologic Neoplasm","NOT_YET_RECRUITING","2024-06-25",{"date":71,"type":72},"2024-06-28","ACTUAL",{"date":74,"type":60},"2024-07-01",{"date":76,"type":60},"2027-06-30",{"name":5,"class":6},1]